{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:06:48Z","timestamp":1774400808494,"version":"3.50.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Carboplatin is a renally excreted antineoplastic drug associated with myelotoxic effects. Doses are calculated according to the Calvert formula. The change from Cockcroft-Gault (CG) to the race-free Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) may have an impact on doses. The aim of the study was to evaluate the difference in carboplatin doses based on estimated glomerular filtration rate (eGFR) calculated using the two different equations (i.e., CG and CKD-EPI) applied to a real-world dataset of carboplatin administrations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>Retrospective study simulating the effect of switching to CKD-EPI on doses calculated using CG. Real-world data were collected on all carboplatin doses administered in a general hospital oncology day-care unit during 2023. Doses originally calculated using CG estimates were recalculated using CKD-EPI results. A Bland-Altman analysis was performed to assess the discrepancies between the two equations. Correlations with anthropometric data were examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>A total of 487 cycles were administered to 126 patients with a mean age of 58.3\u00a0years (SD 12.6), 60.3% were female. There was a significant mean difference (p &amp;lt; 0.001) with a moderate effect (Cohen\u2019s d = 0.474) between clearance calculated with CG and eGFR calculated with CKD-EPI. CKD-EPI calculated doses had a mean 52\u00a0mg higher (limits of agreement \u2212107 + 211). Percentage differences between CKD-EPI and CG doses ranged from +70.9% (CG = 405\u00a0mg, CKD-EPI = 692\u00a0mg) to \u221224.3% (CG = 684\u00a0mg, CKD-EPI = 518\u00a0mg). Differences were strongly correlated with body mass index (BMI) (p &amp;lt; 0.001, R = 0.681).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Clinically relevant differences were found between carboplatin doses calculated with CG and CKD-EPI. These differences were more relevant in male patients with low BMI.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1605458","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T05:14:16Z","timestamp":1749618856000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Influence of the estimated glomerular filtration rate equation on carboplatin dosing: a real-world study"],"prefix":"10.3389","volume":"16","author":[{"given":"Ana Rita","family":"Fortunato","sequence":"first","affiliation":[]},{"given":"C\u00e1tia","family":"Barbosa","sequence":"additional","affiliation":[]},{"given":"Ariana","family":"Araujo","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Fernandez-Llimos","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"1","author":"Bland","year":"1986","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11096-014-0054-3","article-title":"Drug-induced anaemia: a decade review of reporting to the Italian Pharmacovigilance data-base","volume":"37","author":"Carnovale","year":"2015","journal-title":"Int. J. Clin. Pharm."},{"key":"B4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s11096-023-01677-8","article-title":"Discrepancies among equations to estimate the glomerular filtration rate for drug dosing decision making in aged patients: a cross sectional study","volume":"46","author":"Castel-Branco","year":"2024","journal-title":"Int. J. Clin. Pharm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1681\/ASN.2020060833","article-title":"Prediction of kidney drug clearance: a comparison of tubular secretory clearance and glomerular filtration rate","volume":"32","author":"Chen","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron."},{"key":"B7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/BF00292413","article-title":"Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients","volume":"23","author":"Colombo","year":"1989","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1053\/j.ajkd.2023.01.445","article-title":"A prospective cross-sectional study on the performance of the 2021 CKD-EPI equations without race in a multiracial population of adults with solid tumors in Brazil","volume":"82","author":"Costa","year":"2023","journal-title":"Am. J. Kidney Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00280-002-0494-7","article-title":"Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin","volume":"50","author":"De Jonge","year":"2002","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","article-title":"A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney Disease","volume":"79","author":"Delgado","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s002800000260","article-title":"Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing","volume":"47","author":"Donahue","year":"2001","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2165\/00003088-199733030-00002","article-title":"Clinical pharmacokinetics and dose optimisation of carboplatin","volume":"33","author":"Duffull","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.amjmed.2016.08.019","article-title":"Creatinine clearance is not equal to glomerular filtration rate and cockcroft-gault equation is not equal to CKD-EPI collaboration equation","volume":"129","author":"Fernandez-Prado","year":"2016","journal-title":"Am. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1200\/JCO.2017.72.7578","article-title":"New model for estimating glomerular filtration rate in patients with cancer","volume":"35","author":"Janowitz","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s11096-023-01656-z","article-title":"How to manage the dose of drugs in cancer patients with acute kidney injury, practical recommendations","volume":"46","author":"Janus","year":"2024","journal-title":"Int. J. Clin. Pharm."},{"key":"B17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40262-025-01492-6","article-title":"Opportunities for precision dosing of cytotoxic drugs in non-small cell lung cancer: bridging the gap in precision medicine","volume":"64","author":"Kicken","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"B18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann. Intern Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"7171","DOI":"10.1158\/1078-0432.CCR-17-1344","article-title":"Therapeutic drug monitoring of carboplatin in high-dose protocol (TI-CE) for advanced germ cell tumors: pharmacokinetic results of a phase II multicenter study","volume":"23","author":"Moeung","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1177\/1078155218805136","article-title":"Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL\/min: to cap or not to cap? A retrospective analysis and review","volume":"25","author":"Morrow","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","article-title":"Simplified calculation of body-surface area","volume":"317","author":"Mosteller","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s11096-023-01697-4","article-title":"Effects of inpatient creatinine testing frequency on acute kidney injury identification and staging: a historical cohort study","volume":"46","author":"Oliveira","year":"2024","journal-title":"Int. J. Clin. Pharm."},{"key":"B24","volume-title":"Sur l'homme et le d\u00e9veloppement de ses facult\u00e9s ou Essai de physique sociale","author":"Quetelet","year":"1835"},{"key":"B25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","article-title":"Molecular mechanisms of resistance and toxicity associated with platinating agents","volume":"33","author":"Rabik","year":"2007","journal-title":"Cancer Treat. Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"100401","DOI":"10.1016\/j.esmoop.2022.100401","article-title":"Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers","volume":"7","author":"Samani","year":"2022","journal-title":"ESMO Open"},{"key":"B27","volume-title":"International consensus guideline on anticancer drug dosing in kidney dysfunction. St Leonards","author":"Sandhu","year":"2022"},{"key":"B28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.34067\/KID.0000000000000349","article-title":"Carboplatin dosing on the basis of renal function: 30+ years after Calvert","volume":"5","author":"Schwenk","year":"2024","journal-title":"Kidney360"},{"key":"B29","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s11096-024-01709-x","article-title":"Unveiling the future: precision pharmacovigilance in the era of personalized medicine","volume":"46","author":"Silva","year":"2024","journal-title":"Int. J. Clin. Pharm."},{"key":"B30","doi-asserted-by":"publisher","first-page":"zxae317","DOI":"10.1093\/ajhp\/zxae317","article-title":"Moving forward from Cockcroft-Gault creatinine clearance to race-free estimated glomerular filtration rate to improve medication-related decision-making in adults across healthcare settings: a consensus of the National Kidney Foundation Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions","author":"St Peter","year":"2024","journal-title":"Am. J. Health Syst. Pharm."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1177\/00220345920710121601","article-title":"Robustness of the t test applied to data distorted from normality by floor effects","volume":"71","author":"Sullivan","year":"1992","journal-title":"J. Dent. Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/1078155220978446","article-title":"Accurate determination of glomerular filtration rate in adults for carboplatin dosing: moving beyond Cockcroft and Gault","volume":"27","author":"Tsang","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","article-title":"The ASA statement on p-values: context, process, and purpose","volume":"70","author":"Wasserstein","year":"2016","journal-title":"Am. Stat."},{"key":"B34","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00280-019-04020-z","article-title":"Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance","volume":"85","author":"White-Koning","year":"2020","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1605458\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T05:14:18Z","timestamp":1749618858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1605458\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":34,"alternative-id":["10.3389\/fphar.2025.1605458"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1605458","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"article-number":"1605458"}}